The European Commission has approved, under the EU Merger Regulation, the proposed acquisition of Acelity, Inc. (“Acelity”) by 3M Company (“3M”), both of the US. Acelity and 3M are both active in the supply of advanced wound care products.
In particular, they are active in the supply of moist advanced wound care products, which are medical devices that provide a moist environment that can encourage healing and tissue growth in wounds that have difficulty healing in normal conditions.
In addition, Acelity is a supplier of negative pressure wound therapy devices and kits and 3M is a supplier of film drapes and barrier films, which are used together with negative pressure wound therapy devices and included in certain kits.
The Commission concluded that the proposed transaction would raise no horizontal competition concerns given the companies’ moderate combined market shares in the supply of advanced wound care products (or any plausible sub-segmentations) and the presence of a number of competitors in these markets. Moreover, the Commission did not find any anti-competitive vertical or conglomerate effects resulting from the combination of these businesses.
Full Content: Europa
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI